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Abstract
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists
(VKA) in non-cancer patients with venous thromboembolism (VTE), and long-term therapy
with low-molecular weight heparin (LMWH) for those with cancer. We used data from
RIETE (international registry of patients with VTE) to report the use of long-term anticoagu-
lant therapy over time and to identify predictors of anticoagulant choice (regarding interna-
tional guidelines) in patients with- and without cancer. Among 35,280 patients without
cancer, 82% received long-term VKA (but 17% started after the first week). Among 4,378
patients with cancer, 66% received long term LMWH as monotherapy. In patients without
cancer, recent bleeding (odds ratio [OR] 2.70, 95% CI 2.26–3.23), age >70 years (OR 1.15,
95% CI 1.06–1.24), immobility (OR 2.06, 95% CI 1.93–2.19), renal insufficiency (OR 2.42,
95% CI 2.15–2.71) and anemia (OR 1.75, 95% CI 1.65–1.87) predicted poor adherence to
guidelines. In those with cancer, anemia (OR 1.83, 95% CI 1.64–2.06), immobility (OR 1.51,
95% CI 1.30–1.76) and metastases (OR 3.22, 95% CI 2.87–3.61) predicted long-term
LMWH therapy. In conclusion, we report practices of VTE therapy in real life and found that
a significant proportion of patients did not receive the recommended treatment. The per-
ceived increased risk for bleeding has an impact on anticoagulant treatment decision.
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Introduction
For many years, the American College of Chest Physicians (ACCP) recommend that patients
with acute venous thromboembolism (VTE) to be treated initially with parenteral anticoagula-
tion (low-molecular-weight heparin [LMWH], fondaparinux or unfractionated heparin
[UFH]) (Grade 1B) [1]. Then, for patients without cancer they suggest early initiation (eg,
same day as parenteral therapy is started) of vitamin K antagonists (VKA) over LMWH (Grade
2C). In patients with active cancer, concordant clinical trials lead to a specific recommendation
in favour of LMWH over VKA therapy since 2004 (Grade 2B) [1]. However, the implementa-
tion of recommendations on practices is the only relevant feature but little is known about pat-
terns of management of VTE in real life, particularly after hospital discharge. Such information
could possibly contribute to identify remediable gaps in patient care.
The RIETE (Registro Informatizado de Enfermedad TromboEmbólica) Registry is an ongo-
ing, multicenter, international (Spain, Italy, France, Israel, Greece, Switzerland, Czech Republic
and Macedonia), observational registry of consecutive patients with symptomatic, objectively
confirmed, acute VTE. It started in Spain in 2001, and 6 years later the database was translated
into English with the aim to expand the Registry to other countries, ultimately allowing physi-
cians worldwide to use the database to select the most appropriate therapy for their patients.
Data from this registry have been used to evaluate outcomes after acute VTE, such as the fre-
quency of recurrent VTE, bleeding and mortality, and risk factors for these outcomes [2–5]. In
the current analysis, we evaluated anticoagulant practices for VTE treatment over more than
10 years, and tried to identify determinants and patient-related factors for VTE management,
according to international guidelines.
Patients and Methods
Consecutive patients with symptomatic, acute deep vein thrombosis (DVT) or pulmonary em-
bolism (PE), confirmed by objective tests (compression ultrasonography or contrast venogra-
phy for DVT; helical CT-scan or ventilation-perfusion lung scintigraphy for PE), were enrolled
in RIETE. Patients were excluded if they were currently participating in a therapeutic clinical
trial with a blinded therapy. All patients (or their relatives) provided written or oral consent for
participation in the registry, in accordance with local ethics committee requirements.
We certify that RIETE counts with IRB's approval, always in accordance with the internal
requirements of each of the centers participating. This analysis was approved by the Institu-
tional Review Board (IRB) of Hospital Universitari Germans Trias i Pujol (Badalona, Spain)
and the NorthShore University HealthSystem (Evanston, Illinois, USA). As to the need for
written consent, RIETE started in 2001 and then oral consent was enough. For France we got
the approval of the INSERM Ethical committee for oral consent solely, as it is only an epidemi-
ological study. However, as more and more centers have been joining us, most of them have
obtained approval only if consent was written. We have the copies of these approvals.
Physicians participating in the RIETE registry ensured that eligible patients were consecu-
tively enrolled. Data were recorded on to a computer-based case report form at each participat-
ing hospital and submitted to a centralized coordinating center through a secure website. The
study coordinating center assigned patients with a unique identification number to maintain
patient confidentiality and was responsible for all data management. Data quality was regularly
monitored electronically, including checks to detect inconsistencies or errors, which were re-
solved by contacting the local coordinators. Data quality was also monitored by periodic visits
to participating hospitals by contract research organizations that compared medical records
with the submitted data.
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Baseline variables
The following parameters were recorded when the qualifying episode of VTE was diagnosed:
patient's gender, age, and body weight and height; presence of coexisting conditions; concomi-
tant therapies; additional risk factors for VTE including active cancer (defined as newly diag-
nosed cancer or cancer that is being treated [i.e. surgery, chemotherapy, radiotherapy,
hormonal, support therapy, or combined treatments]) and prior VTE; laboratory data, and use
of anticoagulant therapy (drug, dose, date of start and date of discontinuation for each drug).
Treatment and Follow-up
Patients were managed according to the clinical practice of each participating hospital (i.e.,
there was no standardization of treatment). Patients were followed-up for up to 3 months in
the outpatient clinic. During each visit, any signs or symptoms suggesting PE recurrences or
bleeding complications were noted. Each episode of clinically suspected recurrent VTE was in-
vestigated by repeat CUS ultrasonography, lung scanning, helical-CT scan or pulmonary angi-
ography as appropriate. Most outcomes were classified as reported by the clinical centers.
However, if staff at the coordinating center were uncertain how to classify a reported outcome,
that event was reviewed by a central adjudicating committee (less than 10% of events).
Indicators for VTE treatment description
The ACCP Consensus Guidelines on Antithrombotic Therapy1 was used as a benchmark for qual-
ity of VTE care. Since 2004 and consistently in 2008 and 2012, initial treatment using heparin or
LMWHwith a VKA bridging at day 1 has been recommended for non-cancer-related VTE. In the
same recommendations and in line with publication of major clinical trials, 3–6 months LMWH
therapy has become the recommended strategy for treating patients with cancer-related VTE.
Therefore, we used the following indicators for VTE treatment description: long-term thera-
py was the treatment followed by the patient 7 days after the thromboembolic treatment. Pa-
tients were classified in two different strategies: long-term LMWH therapy and long-term
VKA. For patients receiving long-term VKA, we separated patients starting VKA within the
first week of therapy; and those receiving VKA after the first week of therapy. We reported sep-
arately patients receiving fondaparinux as initial VTE therapy.
Statistical analysis
Every test of two proportions was a Student's t test for independent samples with a binary variable
as the response (0/1). Every test of twomeans was a Student’s t test (if variances were homoge-
neous) or aWelch’s test (if variances were heterogeneous). Logistic regression models were used
to examine the individual relationship between each variable and the choice of treatment in the
two populations. We compared baseline characteristics of patients who were treated with: a) VKA
starting within the first week; b) VKA starting beyond the first week and c) long-term LMWH
therapy using chi-square tests for categorical variables (or Fisher exact test where appropriate)
and ANOVA test for continuous variables. Two multivariate analyses were performed: one to
identify predictors of starting VKAwithin the first week versus VKA starting beyond the first
week or long-term LMWH in non-cancer patients; and a second analysis to identify predictors of
VKA versus LMWH therapy in patients with cancer. We chose as covariates all variables with a
p value<0.02 on univariate analysis and those considered by expert opinion. Logistic regression
analyses were performed using a forward stepwise method with a p<0.10 and p>0.05 as inclusion
and exclusion criteria using a score test for likelihood ratio criteria. All analyses were performed
using a commercial software package (SPSS 20 for Mac, SPSS Inc., and Chicago, IL, USA).
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Results
Up to October 2013, 48,481 patients were recruited in RIETE. Only patients receiving VKA
starting within the first 90 days after initial therapy with UFH or LMWH, or those treated with
long-term therapy LMWH after an initial therapy with UFH or LMWH, were considered for
the analysis. The following patients were not considered: 4,787 treated with rivaroxaban or
combinations, 698 with thrombolytics, 608 undergoing an inferior vena cava filter, 26 receiving
no anticoagulants and 927 experiencing an adverse event within the first 5 days. Thus, 41,625
patients were considered for the current study. Major demographic features are summarized in
Table 1 for non-cancer patients and in Table 2 for those with cancer, according to choice of
long-term therapy (VKA or LMWH). Long-term therapy is presented according to the country
in non-cancer patients (Table 3) and in those with cancer (Table 4).
Table 1. Patients without cancer: Clinical characteristics according to long-term anticoagulant therapy.
VKA start <7 days VKA start >7 days LMWH alone
Patients
N 22,986 6,041 6,253
Clinical characteristics
Gender (males) 11,313 (49%) 2,893 (48%) 2,526 (40%)‡
Mean age (years±SD) 64±18 63±18‡ 68±20‡
Age >75 years 8,332 (36%) 2,015 (33%)‡ 3,131 (50%)‡
Body weight (kg±SD) 76±15 76±15 71±15‡
Underlying conditions
Chronic heart failure 1,473 (6.4%) 392 (6.5%) 580 (9.3%)‡
Chronic lung disease 2,530 (11%) 683 (11%) 683 (11%)
CrCl level 30–60 ml/min 7,111 (31%) 1,867 (31%) 2,477 (40%)‡
CrCl levels <30 mL/min 1,098 (4.8%) 273 (4.5%) 2,105 (12%)‡
Recent major bleeding 183 (0.8%) 141 (2.3%)‡ 268 (4.3%)‡
Anemia 5,248 (23%) 1,834 (30%)‡ 2,618 (42%)‡
Chronic liver disease 104 (0.5%) 33 (0.5%) 53 (0.8%)‡
Inﬂammatory bowel disease 78 (0.3%) 34 (0.6%)* 48 (0.8%)‡
Risk factors for VTE
Postoperative 2,250 (9.8%) 741 (12%)‡ 720 (12%)‡
Immobility 4 days 4,913 (21%) 1,454 (24%)‡ 2,502 (40%)‡
Estrogen use 1,378 (6.0%) 315 (5.2%)* 177 (2.8%)‡
Pregnancy/puerperium 143 (0.6%) 129 (2.1%)‡ 315 (5.0%)‡
None of the above 14,314 (62%) 3,463 (57%)‡ 2,708 (43%)‡
Prior VTE 3,875 (17%) 968 (16%) 827 (13%)‡
Initial VTE presentation
Pulmonary embolism 11,804 (51%) 3,212 (53%)* 2,536 (41%)‡
Proximal DVT alone 9,255 (40%) 2,350 (39%) 3,094 (49%)‡
Bilateral DVT alone 183 (1.6%) 80 (2.8%)‡ 120 (3.2%)‡
Upper-extremity DVT 533 (4.8%) 155 (5.5%) 245 (6.6%)‡
Abbreviations: VKA, vitamin K antagonists; LMWH, low-molecular-weight heparin; SD, standard deviation; CrCl, creatinine clearance; VTE, venous
thromboembolism; DVT, deep vein thrombosis. Differences between patients starting VKA within the ﬁrst week and the other groups
* p <0.05
‡p <0.001.
doi:10.1371/journal.pone.0128741.t001
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Patients without cancer
Among 35,280 patients without cancer, 22,986 (65%) started VKA within the first week, 6,041
(17%) beyond the first week, and 6,253 (18%) did not switch to VKA and received long-term
LMWH therapy (Table 1). Overall, 65 patients received fondaparinux as initial VTE therapy:
48 (0.2%) started VKA within the first week, 11 (0.2%) beyond the first week and 6 (0.1% re-
ceived long-term LMWH therapy. Compared to patients starting VKA within the first week,
those starting VKA after the first week more likely to have recent bleeding, anemia, inflamma-
tory bowel disease, recent surgery or immobilization, and more likely presented as PE initially
Table 2. Cancer patients: Clinical characteristics according to long-term anticoagulant therapy.
VKA start <7 days VKA start >7 days LMWH alone
Patients
N 1,516 619 4,210
Clinical characteristics
Gender (males) 840 (55%) 350 (57%) 2,243 (53%)
Mean age (years±SD) 70±12 67±13‡ 66±13‡
Age >75 years 632 (42%) 199 (32%) 1176 (28%)
Body weight (kg±SD) 74±13 73±13 71±14‡
Underlying conditions
Chronic heart failure 87 (5.7%) 31 (5.0%) 152 (3.6%)‡
Chronic lung disease 199 (13%) 70 (11%) 377 (9.0%)‡
CrCl level 30–60 ml/min 575 (38%) 226 (37%) 1,454 (35%)
CrCl levels <30 mL/min 87 (5.7%) 30 (4.8%) 253 (6.0%)
Recent major bleeding 15 (1.0%) 18 (2.9%)† 95 (2.3%)†
Anemia 757 (50%) 361 (58%)‡ 2,926 (70%)‡
Cancer characteristics
Metastases 455 (30%) 200 (32%) 2,550 (61%)‡
Initial VTE presentation
Pulmonary embolism 791 (52%) 331 (54%) 2,060 (49%)*
Proximal DVT alone 627 (41%) 246 (40%) 1,952 (46%)‡
Bilateral DVT alone 27 (3.7%) 19 (6.6%)* 143 (6.7%)†
Upper-extremity DVT 46 (6.3%) 32 (11%)* 395 (18%)‡
Abbreviations: VKA, vitamin K antagonists; LMWH, low-molecular-weight heparin; SD, standard deviation; CrCl, creatinine clearance; VTE, venous
thromboembolism; DVT, deep vein thrombosis. Differences between patients staring VKA within the ﬁrst week and the other groups
* p <0.05
†p <0.01
‡p <0.001.
doi:10.1371/journal.pone.0128741.t002
Table 3. Patients without cancer: country and long-term anticoagulant therapy.
VKA start <7 days VKA start >7 days LMWH alone
Patients
N 22,986 6041 6253
Countries
Spain 18,912 (64%) 5236 (18%) 5205 (18%)
France 1195 (74%) 198 (12%) 227 (14%)
Israel 424 (60%) 83 (12%) 199 (28%)
Italy 1622 (70%) 304 (13%) 396 (17%)
Other countries 833 (65%) 220 (17%) 226 (18%)
doi:10.1371/journal.pone.0128741.t003
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(instead of DVT alone). Compared to those under VKA, patients receiving long-term therapy
with LMWHwere more likely to be female and significantly older, weighed less and more likely
had chronic heart failure, renal insufficiency, recent bleeding, anemia, liver disease, chronic in-
flammatory disease, mental disorders (dementia, depression, schizophrenia or bipolar disor-
der), recent surgery, immobility or pregnancy. By contrast, they less likely had prior VTE or
initial VTE presentation as PE.
Patients with cancer
Among 6,345 patients with cancer, 1,516 (24%) started VKA within the first week, 619 (9.8%)
beyond the first week, and 4,210 (66%) received long-term LMWH therapy (Table 2). Overall,
10 patients received fondaparinux as initial VTE therapy: 5 (50%) started VKA within the first
week and 5 (50% received long-term LMWH therapy. Compared with patients starting VKA
within the first week, those starting VKA after the first week were younger and more likely had
recent surgery. Compared to those under VKA, patients receiving long-term therapy with
LMWH were younger, less likely had chronic heart failure, lung disease or renal insufficiency,
and more likely had anemia, immobility or metastases. They less likely had prior VTE or initial
VTE presentation as PE.
Dynamic evolution of anticoagulant prescription
In non-cancer patients, the number of patients receiving VKA on day 6, 10 and 90 was: 19,783,
24,670 and 26,640, respectively (Fig 1). In patients with cancer, the number of LMWH pre-
scriptions decreased steadily over time, reflecting the poorer prognosis of patients with cancer.
The amount of patients receiving VKA on day 6, 10 and 90 was: 2,246, 1,634 and 1,828 respec-
tively (Fig 2). The evolution over time of the different anticoagulant strategies (VKA starting
within the first week, VKA starting beyond the first week, long-term LMWH therapy) since the
beginning of the RIETE registry is displayed in Fig 3. There was an overall stability of anticoag-
ulant strategies in patients without cancer over time. In patients with cancer, there was a dra-
matic increase on long-term LMWH treatment from 2004 on, concomitantly with a decrease
of VKA prescriptions.
Factors associated with poor guidelines adherence
In patients without cancer, female gender, recent bleeding, anemia, recent surgery or immobili-
zation, renal insufficiency, chronic liver disease, inflammatory bowel disease, mental distur-
bances and initial presentation as DVT independently predicted not starting VKA within the
first week (Table 5). Inversely, prior VTE independently predicted a VKA initiation within the
first week.
Table 4. Patients with cancer: country and long-term anticoagulant therapy.
VKA start <7 days VKA start >7 days LMWH alone
Patients
N 1516 619 4210
Countries
Spain 1211 (25%) 515 (11%) 3173 (65%)
France 63 (21%) 21 (7.0%) 215 (72%)
Israel 29 (8.5%) 9 (2.6%) 304 (89%)
Italy 121 (24%) 46 (9.1%) 338 (67%)
Other countries 92 (31%) 28 (9.3%) 180 (60%)
doi:10.1371/journal.pone.0128741.t004
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In cancer patients, age>70 years, chronic heart or lung disease and initial presentation as
PE independently predicted poor adherence to the ACCP recommendations (Table 3). The
presence of metastases, anemia and recent immobility independently predicted the use of long-
term LMWH therapy.
Discussion
The objective of our study was to identify associations of anticoagulant use in the setting of ve-
nous thromboembolism in usual care. To achieve this objective, we obtained clinical practice-
based data from the RIETE registry, the largest database on the management of symptomatic
VTE. Our analyses provide useful information on clinical features of patients, management of
VTE. Our data reveal that only 65% of patients without cancer started VKA within the first
week, and only 66% of those with cancer received LMWH as monotherapy. Among patients
without cancer, 17% started VKA therapy after the first week and 18% received long-term
LMWH for at least the first 3 months.
Major factors to the anticoagulant decision were slightly different according to the presence
or absence of cancer. In patients without cancer, the choice for treatment was driven by factors
Fig 1. Prescription of long-term therapy within the first 90 days in non-cancer patients.
doi:10.1371/journal.pone.0128741.g001
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(recent bleeding, anemia, renal insufficiency, chronic liver disease, inflammatory bowel disease,
mental disturbances) that have been associated with an increased risk for bleeding [6,7]. In pa-
tients with cancer, the choice for anticoagulation strategy was mostly influenced by the pres-
ence of metastases, anemia or immobility [8]. Of note, age and renal insufficiency influenced
differently according to the presence or absence of cancer: In patients without cancer, renal in-
sufficiency not only did not discourage clinicians from prescribing long-term LMWH, but
strongly drove the decision toward long-term LMWH therapy, while age over 70 had no im-
pact. In patients with cancer, renal insufficiency had no impact but age over 70 years discour-
aged clinicians from prescribing the recommended LMWH therapy. A number of studies have
reported a higher incidence of major bleeding events in VTE patients receiving anticoagulant
therapy in real life than in randomized clinical trials, most likely due to the strict exclusion cri-
teria for patients recruited in these trials [9–12]. Thus, it should not be unexpected to find that
the adherence to guidelines in real life was poor, as in other studies [13,14].
Interestingly, there was an evolution over time of anticoagulant strategies in patients with
cancer: the publication of the CANTHANOX, CLOT and LITE studies [15–17] were associated
Fig 2. Prescription of long-term therapy within the first 90 days in patients with cancer.
doi:10.1371/journal.pone.0128741.g002
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Fig 3. Evolution over years of prescriptions of the three modalities of long-term anticoagulant therapy in cancer and non-cancer patients.
doi:10.1371/journal.pone.0128741.g003
Table 5. Variables at baseline independently correlated to poor adherence to guidelines (VKA start <7 days for patients without cancer, and
LMWH alone for patients with cancer).
Patients without cancer p Patients with cancer p
Patient characteristics OR (95% CI) OR (95% CI)
Gender (males) 0.89 (0.84–0.95) <0.001 - -
Age >70 years - - 1.39 (1.24–1.56) <0.001
Chronic heart disease - - 1.50 (1.15–1.95) 0.003
Chronic lung disease - - 1.36 (1.14–1.63) 0.001
Recent major bleeding 2.72 (2.28–3.24) <0.001 - -
Anemia 1.72 (1.62–1.83) <0.001 0.55 (0.49–0.62) <0.001
Postoperative 1.20 (1.09–1.32) <0.001 - -
Immobility 4 days 1.98 (1.86–2.10) <0.001 0.67 (0.58–0.78) <0.001
Prior VTE 0.87 (0.80–0.94) 0.001 - -
Pulmonary embolism (vs. DVT) 0.59 (0.56–0.63) <0.001 1.15 (1.03–1.28) 0.015
CrCl levels >60 mL/min 1 (ref.) - -
CrCl levels 30–60 mL/min 1.40 (1.30–1.52) <0.001 - -
CrCl levels <30 mL/min 2.31 (2.06–2.59) <0.001 - -
Chronic liver disease 1.82 (1.30–2.55) 0.001 - -
Inﬂammatory bowel disease 2.06 (1.44–2.94) <0.001 - -
Mental disturbances 2.82 (2.48–3.21) <0.001 - -
Abbreviations: OR, odds ratio; CI, conﬁdence intervals; CrCl, creatinine clearance; VTE, venous thromboembolism; DVT, deep vein thrombosis.
doi:10.1371/journal.pone.0128741.t005
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in an increase of long-term LMWH prescriptions, as suggested in a previous study [18]. In
non-cancer patients, no change has been observed over 10 years. Repeated recommendations
with a high level of evidence did not result in any implementation in practice. Similar observa-
tions were made for thromboprophylaxis in medical in-patients [19,20].
Current guidelines on antithrombotic therapy provide a critical review of the literature related
to the management of patients with VTE and lay the scientific groundwork for the standard of
care, based largely on data from randomized controlled clinical trials [1]. However, a number of
VTE patients are often excluded from randomized clinical trials. Thus, there is scarce evidence on
what would be the best therapeutic approach for these patients. The RIETE Registry was designed
to gather and analyze data on treatment patterns and outcomes in patients with acute VTE. In
contrast to randomized controlled trials, there is no imposed experimental intervention: manage-
ment is determined solely by physicians. Thus, it provides data on patients with VTE in a real-
world situation with an unselected patient population. Data from RIETE are hypothesis-generat-
ing and provide feedback from real-world clinical situations. Strengths of the current analysis in-
clude that a large number of consecutive unselected patients were enrolled, and that fatal PE is by
far the most important outcome during the treatment of acute PE. In our approach, we studied
patients and treatment related factors contributing to anticoagulant decision. But other factors
may play a role such as cost, reimbursement or need for periodical biological monitoring. Choice
of treatment in patients with and without cancer is also sensitive to the individual patient’s toler-
ance for daily injections and perceived risk for bleeding (by the patient and the physician). Unfor-
tunately, our registry could not assess these parameters. Of note, no country effect was observed.
Conclusion
In conclusion, our results indicate that there are differences in practice from the guidelines, as
starting VKA therapy to treat VTE in patients without cancer, and as using LMWH as mono-
therapy in those with cancer. These differences are likely due to comorbid conditions in pa-
tients with and without cancer and some concern about the risk of bleeding, particularly in
patients who deserve quick VKA initiation. The impact of direct oral anticoagulants (which
seems to have a better safety profile) may modify these unappropriated prescriptions.
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